drugset / Trial / NCT01975298

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01975298

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to assess the efficacy, safety, and tolerability of two doses of laquinimod compared to Avonex®

Timeline

Start
2014-01
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Interferon beta-1a Protein / enzyme biologic 30 ug Intramuscular
Subject Laquinimod Small molecule 0.6 mg Oral
Subject Laquinimod Small molecule 1.2 mg Oral